The companies will work to develop peptide therapeutics that may be effective against multiple coronavirus strains, they said in a release. The agreement builds on a research and licensing partnership announced in 2015.
PeptiDream specialises in constrained peptides, types of amino acids that can carry various cargoes to specific types of cells.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: